{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia4i3i4nhrdbtsrjj7tk6g4qodfoesy73oznroesmapdy47onjjjq",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3minkwtkd5j62"
  },
  "path": "/t/thinking-clearly-about-association-studies-risk-factors-and-causal-salad-included/28679?page=2#post_22",
  "publishedAt": "2026-04-03T13:43:01.000Z",
  "site": "https://discourse.datamethods.org",
  "textContent": "I don’t quite understand the history of the drug you’re describing. If some patients given the drug lived _much_ longer than all historical patients with the same disease and this is why it was granted accelerated approval (even without support from typically-designed RCTs), then why would the same drug be _withdrawn_ from the market for _safety_ -related reasons (??) Wouldn’t patients who know they are _certainly_ going to die in a short time with _out_ treatment be willing to accept treatment with a risky but possibly efficacious drug (?) The fact that it was withdrawn voluntarily suggests that the basis for the approval was suspect (?)…",
  "title": "Thinking Clearly about Association Studies (Risk Factors and Causal Salad included)"
}